SOURCE: Empire Genomics

November 18, 2008 13:02 ET

Empire Genomics and Enzo Life Sciences Combine to Offer Custom Labeled FISH Probe Products & Services

BUFFALO, NY and NEW YORK, NY--(Marketwire - November 18, 2008) - Empire Genomics, LLC and Enzo Life Sciences (ENZ) today announced the availability of custom labeled FISH probes based on high quality and widely used BAC libraries and DNA labeling technologies respectively. These new products will allow researchers and clinicians the ability to identify novel chromosome aberrations and validate array CGH results.

Empire Genomics' access to the Roswell Park BAC clones serve as the base material for creating the custom FISH probes. Empire distributes BAC/PAC libraries from multiple species such as Human, Mouse, Porcine and Chimpanzee to name a few.

Labeling of BAC DNA from clone libraries is performed as a custom service using Enzo Life Sciences' fluorescent dye labeled nucleotides and Nick Translation System. Customers can choose among five different colors comprised of eight distinct dyes for a multiplexed approach to FISH probe analysis. Conversely, BAC DNAs and labeling kits can be ordered separately for customers interested in labeling probes.

"This represents yet another step to complement our high resolution aCGH and genomic products," said Anthony Johnson, President and CEO of Empire Genomics. "We are looked to as the leader in BAC DNA products and this is something we have been asked to provide for quite some time. We are very pleased to help remove a crucial labeling step for our customers and look forward to continually working to reduce variability, costs and time in experiments, partnering with Enzo allows us to do this and maintain the same high quality requirements our customers expect."

"Empire Genomics' expertise, industry leading position and excellent reputation in genomic technologies and systems biology makes the company an ideal business partner," stated Carl W. Balezentis, Ph.D. President, Enzo Life Sciences. "This relationship is a perfect example of two companies working together to leverage the core competencies of each to support a key market need."

These products address a current unmet need of clinical researchers. As a result, the custom labeling service will permit more comprehensive analysis of chromosomal abnormalities while reducing the user error possible from performing the labeling step in the lab.

For more information about the new custom labeled products please visit or

About Empire

Empire Genomics, based in Buffalo, New York, utilizes proprietary techniques to identify and quantify chromosomal abnormalities. Specifically, the company has evolved array-based Comparative Genomic Hybridization (aCGH) by developing microarrays that utilize discrete segments of DNA generated from the RPCI BAC clones. These are of considerable diagnostic value to early stage disease detection and treatment, and streamline the process by eliminating the need to grow cells or obtain large sample amounts. The company was founded on the research experience of Dr. Norma Nowak and her more than 100 peer reviewed research publications. More information on Empire Genomics is available at

About Enzo

Enzo Life Sciences, Inc. is an internationally recognized leader in developing, manufacturing, in-licensing, and commercializing innovative high quality research tools for the biomedical and pharmaceutical markets. With over 30 years of experience and a sizeable patent and technology portfolio, this subsidiary of Enzo Biochem, Inc. offers a comprehensive panel of over 20,000 products. Through outstanding operational capabilities and a progressive e-marketplace, consumers can access both products and scientific expertise in the fields of gene expression, labeling and detection, apoptosis, cellular analysis, signal transduction, drug discovery and several other disease-related research areas. For more information visit our website

Contact Information

  • Contact details:
    Anthony Johnson
    Empire Genomics